-
-
-
-
-
-
-
Clovis Oncology (CLVS) Says CHMP Granted Positive Opinion for its Rubraca Tablets
-
-
-
-
-
-
-
Clovis Oncology (CLVS) Receives Positive Trend Vote from CHMP for Rucaparib Ovarian Cancer Treatment Indication
-
-
-
-
-
-
-
Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application
-
-
-
-
-
-
-
Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress
-
-
-
-
-
-
-
Mizuho Boosts PT on Clovis Oncology (CLVS) to $23 Following Rucaparib NDA Approval
-
-
-
-
-
-
-
Pre-Open Stock Movers 04/13: (RPRX) (ACUR) (MDVN) Higher; (CLVS) (VRX) (S) Lower (more...)
-
-
-
-
-
-
-
Piper Jaffray Assumes Clovis Oncology (CLVS) at Neutral
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

